UBS raises Johnson & Johnson stock price target to $320 on outlook

UBS raised its Johnson & Johnson price target to $320 from $280 (stock at $271.19, +55.73% YoY) while keeping a Buy rating, effectively adding $40 of upside from the prior target. Other analysts also lifted targets (e.g., Guggenheim to $287, Raymond James to $280) citing strong quarterly performance and recent FDA-driven momentum (including Ottava launch and platform coverage). Overall, the newsflow is supportive for JNJ and the broader healthcare/medical devices peer set, but is unlikely to be market-wide.

Analysis

The sellside reset on JNJ reads more like a validation of a quality premium than a fresh earnings catalyst. With the stock already near peak pricing, the incremental upside from another target hike is limited unless management converts the recent operating strength into repeated estimate beats; otherwise the name behaves like a defensive bond proxy and can stall once the enthusiasm fades.

The more interesting second-order effect is relative-value displacement inside large-cap healthcare. If JNJ is proving it can still compound through pharma and device execution, capital may rotate toward names with visible, self-funded growth and away from medtech stories that still rely on longer-dated adoption curves. That makes MDT the cleaner pair short than a broad healthcare basket: the market is being asked to pay today for a 2028-led share thesis, while JNJ has nearer-term proof points.

Contrarian risk: the consensus may be underestimating how much good news is already embedded in JNJ after the recent run. If the next earnings cycle shows only modest revision upside, the multiple can compress even if fundamentals stay fine. The key falsifier is any evidence that pharma momentum normalizes or device launches fail to translate into revenue; that would likely cap JNJ over the next 1-3 months and re-anchor it as a high-quality but not especially cheap defensive.

Key Decisions for Investors

• Initiate a 1-3 month pair trade: long JNJ / short MDT on a relative-strength basis. Target 5-8% outperformance if JNJ continues to convert revisions into price action; stop if MDT shows accelerating PFA/mapping share or JNJ loses $265 on heavy volume.
• Do not chase JNJ outright after the target increase; wait for a pullback toward the prior breakout zone or next earnings confirmation before adding. Near-term risk/reward is asymmetric to the downside if the market decides the rerating is complete.
• For existing JNJ longs, consider selling near-dated upside calls into strength to harvest premium while the stock trades near highs. This monetizes the elevated implied confidence without taking a hard directional view.
• Set an alert on the next JNJ quarter for sequential revenue/margin confirmation in pharma and devices. A single miss on either would likely reverse the upgrade-driven momentum faster than a normal valuation reset.